Literature DB >> 17437620

Mitofusin 2 gene mutation (R94Q) causing severe early-onset axonal polyneuropathy (CMT2A).

C Neusch1, J Senderek, T Eggermann, E Elolff, M Bähr, C Schneider-Gold.   

Abstract

Charcot-Marie-Tooth disease (CMT) has been classified into two types: demyelinating forms (CMT1) and axonal forms (CMT2). Mutations in the CMT2A locus have been linked to the KIF1B and the mitofusin 2 (MFN2) genes. Here, we report a German patient with CMT2 with an underlying spontaneous mutation (c.281G-->A) in the MFN2 gene. Clinically, the patient presented with early-onset CMT that was not associated with additional central nervous system pathology. The disease course was rapidly progressive in the first years and slowed afterwards. We also suggest that single patients with early-onset axonal polyneuropathies should be screened for MFN2 mutations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437620     DOI: 10.1111/j.1468-1331.2006.01688.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  9 in total

Review 1.  A review of genetic counseling for Charcot Marie Tooth disease (CMT).

Authors:  Carly E Siskind; Seema Panchal; Corrine O Smith; Shawna M E Feely; Joline C Dalton; Alice B Schindler; Karen M Krajewski
Journal:  J Genet Couns       Date:  2013-04-21       Impact factor: 2.537

2.  Decreased ceramide underlies mitochondrial dysfunction in Charcot-Marie-Tooth 2F.

Authors:  Nicholas U Schwartz; Ryan W Linzer; Jean-Philip Truman; Mikhail Gurevich; Yusuf A Hannun; Can E Senkal; Lina M Obeid
Journal:  FASEB J       Date:  2018-01-03       Impact factor: 5.191

Review 3.  Causal roles of mitochondrial dynamics in longevity and healthy aging.

Authors:  Arpit Sharma; Hannah J Smith; Pallas Yao; William B Mair
Journal:  EMBO Rep       Date:  2019-10-31       Impact factor: 8.807

4.  Mutation screening of mitofusin 2 in Charcot-Marie-Tooth disease type 2.

Authors:  Donald S McCorquodale; Gladys Montenegro; Ainsley Peguero; Nicole Carlson; Fiorella Speziani; Justin Price; Sean W Taylor; Michel Melanson; Jeffery M Vance; Stephan Züchner
Journal:  J Neurol       Date:  2011-01-22       Impact factor: 4.849

5.  MFN2 mutations cause severe phenotypes in most patients with CMT2A.

Authors:  S M E Feely; M Laura; C E Siskind; S Sottile; M Davis; V S Gibbons; M M Reilly; M E Shy
Journal:  Neurology       Date:  2011-04-20       Impact factor: 9.910

6.  Mutation analysis of MFN2, GJB1, MPZ and PMP22 in Italian patients with axonal Charcot-Marie-Tooth disease.

Authors:  Giorgia Bergamin; Francesca Boaretto; Chiara Briani; Elena Pegoraro; Mario Cacciavillani; Andrea Martinuzzi; Maria Muglia; Andrea Vettori; Giovanni Vazza; Maria Luisa Mostacciuolo
Journal:  Neuromolecular Med       Date:  2014-05-13       Impact factor: 3.843

7.  MFN2 point mutations occur in 3.4% of Charcot-Marie-Tooth families. An investigation of 232 Norwegian CMT families.

Authors:  Geir J Braathen; Jette C Sand; Ana Lobato; Helle Høyer; Michael B Russell
Journal:  BMC Med Genet       Date:  2010-03-29       Impact factor: 2.103

Review 8.  The Role of Impaired Mitochondrial Dynamics in MFN2-Mediated Pathology.

Authors:  Mashiat Zaman; Timothy E Shutt
Journal:  Front Cell Dev Biol       Date:  2022-03-24

Review 9.  Animal Models of CMT2A: State-of-art and Therapeutic Implications.

Authors:  Roberta De Gioia; Gaia Citterio; Elena Abati; Monica Nizzardo; Nereo Bresolin; Giacomo Pietro Comi; Stefania Corti; Federica Rizzo
Journal:  Mol Neurobiol       Date:  2020-08-27       Impact factor: 5.590

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.